These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24006142)

  • 21. Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies.
    Dalakas MC
    Curr Opin Neurol; 2020 Oct; 33(5):545-552. PubMed ID: 32833750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab as Adjunct Maintenance Therapy for Refractory Juvenile Myasthenia Gravis.
    Zingariello CD; Elder ME; Kang PB
    Pediatr Neurol; 2020 Oct; 111():40-43. PubMed ID: 32951658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-lasting treatment effect of rituximab in MuSK myasthenia.
    Díaz-Manera J; Martínez-Hernández E; Querol L; Klooster R; Rojas-García R; Suárez-Calvet X; Muñoz-Blanco JL; Mazia C; Straasheijm KR; Gallardo E; Juárez C; Verschuuren JJ; Illa I
    Neurology; 2012 Jan; 78(3):189-93. PubMed ID: 22218276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab for myasthenia gravis: three case reports and review of the literature.
    Stieglbauer K; Topakian R; Schäffer V; Aichner FT
    J Neurol Sci; 2009 May; 280(1-2):120-2. PubMed ID: 19272616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myasthenia gravis: emerging new therapy options.
    Sieb JP
    Curr Opin Pharmacol; 2005 Jun; 5(3):303-7. PubMed ID: 15907918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis.
    Marino M; Basile U; Spagni G; Napodano C; Iorio R; Gulli F; Todi L; Provenzano C; Bartoccioni E; Evoli A
    Front Immunol; 2020; 11():613. PubMed ID: 32431692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective response to rituximab in a young child with MuSK-associated myasthenia gravis.
    Govindarajan R; Iyadurai SJ; Connolly A; Zaidman C
    Neuromuscul Disord; 2015 Aug; 25(8):651-2. PubMed ID: 25998611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab in myasthenia gravis: a "to be or not to be" inhibitor of T cell function.
    Marino M; Bartoccioni E; Alboini PE; Evoli A
    Ann N Y Acad Sci; 2018 Feb; 1413(1):41-48. PubMed ID: 29369382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis.
    Sun F; Ladha SS; Yang L; Liu Q; Shi SX; Su N; Bomprezzi R; Shi FD
    Muscle Nerve; 2014 Apr; 49(4):487-94. PubMed ID: 23868194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis.
    Catzola V; Battaglia A; Buzzonetti A; Fossati M; Scuderi F; Fattorossi A; Evoli A
    J Neurol; 2013 Aug; 260(8):2163-5. PubMed ID: 23749295
    [No Abstract]   [Full Text] [Related]  

  • 31. Prolonged improvement after rituximab: two cases of resistant muscle-specific receptor tyrosine kinase + myasthenia gravis.
    Burusnukul P; Brennan TD; Cupler EJ
    J Clin Neuromuscul Dis; 2010 Dec; 12(2):85-7. PubMed ID: 21386776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab therapy for Morvan syndrome associated with myasthenia gravis.
    Weiss M
    Muscle Nerve; 2012 Jul; 46(1):139-40. PubMed ID: 22693003
    [No Abstract]   [Full Text] [Related]  

  • 33. MuSK-antibody positive pure ocular myasthenia gravis.
    Hanisch F; Eger K; Zierz S
    J Neurol; 2006 May; 253(5):659-60. PubMed ID: 16311895
    [No Abstract]   [Full Text] [Related]  

  • 34. Rituximab in late-onset myasthenia gravis is safe and effective.
    Sahai SK; Maghzi AH; Lewis RA
    Muscle Nerve; 2020 Sep; 62(3):377-380. PubMed ID: 32239711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complicated pathophysiology behind rituximab-induced persistent hypogammaglobulinemia.
    Kano G; Nakatani T; Yagi K; Sakamoto I; Imamura T
    Immunol Lett; 2014; 159(1-2):76-8. PubMed ID: 24184906
    [No Abstract]   [Full Text] [Related]  

  • 36. Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review.
    Nelson RP; Pascuzzi RM; Kessler K; Walsh LE; Faught PP; Ramanuja S; Pescovitz MD; Loehrer PJ
    J Clin Neuromuscul Dis; 2009 Jun; 10(4):170-7. PubMed ID: 19494727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful treatment and clearing of circulating CD19-positive cells by rituximab in a child with idiopathic membranous nephropathy.
    Zhu B; Huang J
    Pediatr Nephrol; 2011 Apr; 26(4):637-8. PubMed ID: 21046167
    [No Abstract]   [Full Text] [Related]  

  • 38. Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study.
    Litchman T; Roy B; Kumar A; Sharma A; Njike V; Nowak RJ
    J Neurol Sci; 2020 Apr; 411():116690. PubMed ID: 32028072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antigen specific B cells in myasthenia gravis patients.
    Takata K; Kinoshita M; Mochizuki H; Okuno T
    Immunol Med; 2020 Jun; 43(2):65-71. PubMed ID: 32046601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study.
    Dos Santos A; Noury JB; Genestet S; Nadaj-Pakleza A; Cassereau J; Baron C; Videt D; Michel L; Pereon Y; Wiertlewski S; Magot A
    Eur J Neurol; 2020 Nov; 27(11):2277-2285. PubMed ID: 32526053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.